29 Mar 2012 07:00
e-Therapeutics plc (AIM:ETX) announces that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company's anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.
A phase I trial in the UK will recruit patients with a variety of solid tumours, while a US investigator-led trial will enrol patients with primary or secondary brain cancers. Further details of each trial will be provided when its first patient is treated.
Professor Malcolm Young, CEO of e-Therapeutics, said: "We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year."
e-Therapeutics' latest expectations for its other products are that ETX1153c (for C. difficile infection) will start phase I in Q2 or Q3, that ETS6103 (for major depressive disorder) will enter phase IIb in Q3 and that ETX1153a (for MRSA infection) will start phase I in Q4.
Contacts:
e-Therapeutics plc Malcolm Young / Daniel ElgerTel: +44 (0) 7909 915 068www.etherapeutics.co.uk
Panmure Gordon (UK) Limited Andrew Burnett / Fred WalshTel: +44 (0) 20 7459 3600www.panmure.com
College Hill Melanie Toyne Sewell / Jayne CrookTel: +44 (0) 20 7457 2020Email: e-therapeutics@collegehill.com
CommStrat Group (US) Ted AgneTel: (+1) 781 631 3117Email: edagne@comstratgroup.com
About e-Therapeutics
e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery activity is focused in cancer and degenerative diseases of the nervous system and its development effort on four clinical candidates spanning cancer, psychiatric disorders and infectious diseases. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.
Copyright Business Wire 2012